Stephens Consulting, LLC Nurix Therapeutics, Inc. Transaction History
Stephens Consulting, LLC
- $399 Billion
- Q1 2025
A detailed history of Stephens Consulting, LLC transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Stephens Consulting, LLC holds 30 shares of NRIX stock, worth $307. This represents 0.0% of its overall portfolio holdings.
Number of Shares
30Holding current value
$307% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding NRIX
# of Institutions
185Shares Held
67MCall Options Held
318KPut Options Held
42.4K-
Black Rock Inc. New York, NY6.82MShares$69.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.35MShares$44.5 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.19MShares$42.9 Million6.18% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$39.8 Million0.81% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.01MShares$30.8 Million0.01% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $483M
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...